<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746587</url>
  </required_header>
  <id_info>
    <org_study_id>OR-ARI-GAU-01</org_study_id>
    <nct_id>NCT03746587</nct_id>
  </id_info>
  <brief_title>Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3</brief_title>
  <official_title>Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orphazyme</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orphazyme</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients
      with Gaucher Disease Type 1 or 3
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluating the response of 3 dose levels of arimoclomol on various pharmacodynamic biomarkers
      in blood and cerebrospinal fluid as indicators of enhanced GBA in Gaucher Disease Type 1 or
      3.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blinded, randomized, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage change in serum chitotriosidase levels from baseline to 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in weight curve (Khadilkar and Khadilkar, 2011) measured in kilograms, at every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in length curve (Khadilkar and Khadilkar, 2011) measured in meters at every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maturation Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Age at pubertal onset (Tanner Stage II) for subjects who had not reached puberty at screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maturation Endpoint</measure>
    <time_frame>6 - 12 months</time_frame>
    <description>Tanner Staging at baseline, 6 months and at least every 12 months (Tanner stage I-IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in size of liver and spleen assessed by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Gaucher Disease, Type 1</condition>
  <condition>Gaucher Disease, Type 3</condition>
  <arm_group>
    <arm_group_label>Arimoclomol I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arimoclomol, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arimoclomol II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arimoclomol, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arimoclomol III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arimoclomol, oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule matching experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimoclomol</intervention_name>
    <description>Arimoclomol in 3 different dosages</description>
    <arm_group_label>Arimoclomol I</arm_group_label>
    <arm_group_label>Arimoclomol II</arm_group_label>
    <arm_group_label>Arimoclomol III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Be able to understand and voluntarily sign informed consent

          -  A diagnosis GD, either Type 1 or Type 3

          -  For GD3 at least 1 neurological symptom

          -  Age ≥ 4 years and ≤ 60 years at the time of enrolment

          -  Plasma or serum chitotriosidase activity greater than 3 times the upper limit of
             normal.

        Key Exclusion Criteria:

          -  Recipient of a liver transplant or planned liver transplantation during the course of
             the study.

          -  Splenectomy within 4 months of study entry or planned splenectomy during the course of
             the study.

          -  Severe liver damage.

          -  Severe renal insufficiency.

          -  Body weight &lt; 10 kg.

        Other inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aabha Nagral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaslok Hospital and Reseach Centre, Mumbai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>4000012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital and Reseach Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEM HOSPITAL Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College and Hospital.</name>
      <address>
        <city>Vellore</city>
        <state>Tamilnadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

